Tri-I Stimulating Access to Research in Residency program (Tri-I StARR - NIAID)

Tri-I 促进住院医师研究项目 (Tri-I StARR - NIAID)

基本信息

  • 批准号:
    10592130
  • 负责人:
  • 金额:
    $ 44.89万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-06-15 至 2028-05-31
  • 项目状态:
    未结题

项目摘要

Abstract: Despite the irreplaceable contributions of physician-scientists to clinical, the pipeline of clinician-scientist trainees remains on the decline. A critical barrier to the physician-scientist career is the lack of protected time and access to research mentorship available to physicians during clinical training. With the heightened acuity, volume and complexities of modern medicine, clinical training has increasingly focused on the acquisition and application of existing, rather than generation of new, knowledge. An unfortunate consequence of this shift in focus is the increasing compartmentalization of scientific training into fragments of time that are inadequate to provide the training and continuity needed to become proficient in the scientific investigation. The Tri- Institutional Stimulating Access to Research during Residency (Tri-I StARR) program seeks to remedy this deficiency by developing an integrated, longitudinal mentored research training program that will lead to the development, implementation, and evaluation of new clinical interventions to prevent, diagnose, treat and ameliorate health disparities of disorders of infectious, immunologic and inflammatory etiologies, with mentorship from across Weill Cornell Medicine, Rockefeller University, and Memorial Sloan Kettering. Tri-I- StARR will train residents on an integrated clinical-research pathway across 3 departments: Pediatrics, Medicine, and Pathology in areas along the full biomedical research continuum and include the themes of healthcare disparities and health and disease over the life course. The program proposes four training aims: (1) Acquisition of skills in the scientific method and design of hypothesis-based projects to address human diseases across the lifespan and their inequities, (2) Individualized, multidisciplinary mentorship in the design and completion of a research project, (3) Development of short, intermediate, and long term IDPs that integrate scientific and clinical training within and across career stages, and (4) Active engagement in horizontal and vertical networking among physician-scientists within and across career stages and institutions. The Tri-I-StARR will be led by an Executive Committee (EC) consisting of Kyu Rhee, MD PhD (Medicine), Sallie Permar, MD, PhD (Pediatrics), and Ethel Cesarman, MD (Pathology), an Expanded Executive Committee (EEC) of Residency Program Directors and Program Coordinators, and a team of 36 multi- departmental, multi-disciplinary, well-funded, and experienced faculty preceptors. Three Resident-Investigators each year will be supported for 12 months of research with the options to add an additional 12 months. Upon completion, trainees will be capable of transitioning to research-intense fellowship training, successfully competing for follow-on funding opportunities, including the K38, that will enable them to become the next generation of physicians leading and mentoring trainees in clinically-oriented research. This program will fulfill the urgent need for: 1) more full-time academic physician-researchers in medical schools throughout the country, and 2) innovations and clinical translation of novel strategies to improve health across the lifespan.
摘要: 尽管医生科学家对临床的贡献不可替代,但临床医生科学家的管道 受训人员仍在减少。医生-科学家职业生涯的一个关键障碍是缺乏保护时间 以及在临床培训期间为医生提供的研究指导。随着敏锐度的提高, 现代医学的数量和复杂性,临床培训越来越多地集中在获取和 应用现有知识,而不是产生新知识。这种转变的一个不幸后果是, 重点是越来越多的科学培训分割成碎片的时间,不足以 提供精通科学调查所需的培训和连续性。三- 住院期间机构刺激获得研究(Tri-I StARR)计划旨在解决这一问题 通过开发一个综合的,纵向的指导研究培训计划,将导致 开发、实施和评估新的临床干预措施,以预防、诊断、治疗和 改善感染性、免疫性和炎性病因疾病的健康差异, 来自威尔康奈尔医学院,洛克菲勒大学和纪念斯隆凯特琳的导师。三I StARR将在3个部门的综合临床研究途径上培训居民:儿科, 医学和病理学在领域沿着完整的生物医学研究连续体,包括主题 医疗保健差距以及生命过程中的健康和疾病。该计划提出了四个培训目标: (1)掌握科学方法和设计基于假设的项目的技能,以解决人类 疾病在整个生命周期和他们的不平等,(2)个性化,多学科的指导设计 (3)培养短期、中期和长期国内流离失所者, 在职业生涯阶段内和跨职业生涯阶段整合科学和临床培训,以及(4)积极参与 在医生-科学家之间建立横向和纵向网络,并在职业阶段和机构之间建立网络。 Tri-I-StARR将由执行委员会(EC)领导,执行委员会由Kyu Rhee,MD PhD(医学), Sallie Permar,医学博士,博士(儿科)和Ethel Cesarman,医学博士(病理学),一个扩展的执行官 委员会(EEC)的居住计划主任和计划协调员,以及一个团队的36多- 部门,多学科,资金充足,经验丰富的教师导师。三名住院研究员 每年将支持12个月的研究,并可选择增加12个月。后 完成后,学员将能够成功过渡到研究密集型奖学金培训, 竞争包括K38在内的后续融资机会,这将使他们成为下一个 在临床导向的研究中领导和指导受训者的医生的一代。该计划将满足 迫切需要:1)在整个医学院校中有更多的全职学术医生研究人员。 国家,和2)创新和临床翻译的新战略,以改善整个生命周期的健康。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ETHEL CESARMAN其他文献

ETHEL CESARMAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ETHEL CESARMAN', 18)}}的其他基金

Next-Gen Oncopathology Program
下一代肿瘤病理学计划
  • 批准号:
    10676213
  • 财政年份:
    2022
  • 资助金额:
    $ 44.89万
  • 项目类别:
Rapid Sample-to-Answer Diagnosis of Kaposi's Sarcoma Across Sub-Saharan Africa using KS-COMPLETE
使用 KS-COMPLETE 对撒哈拉以南非洲地区的卡波西肉瘤进行快速样本到答案诊断
  • 批准号:
    10416778
  • 财政年份:
    2022
  • 资助金额:
    $ 44.89万
  • 项目类别:
Rapid Sample-to-Answer Diagnosis of Kaposi's Sarcoma Across Sub-Saharan Africa using KS-COMPLETE
使用 KS-COMPLETE 对撒哈拉以南非洲地区的卡波西肉瘤进行快速样本到答案诊断
  • 批准号:
    10642906
  • 财政年份:
    2022
  • 资助金额:
    $ 44.89万
  • 项目类别:
B cell determinants of EBV latency
EBV 潜伏期的 B 细胞决定因素
  • 批准号:
    10541734
  • 财政年份:
    2022
  • 资助金额:
    $ 44.89万
  • 项目类别:
B cell determinants of EBV latency
EBV 潜伏期的 B 细胞决定因素
  • 批准号:
    10701826
  • 财政年份:
    2022
  • 资助金额:
    $ 44.89万
  • 项目类别:
Regulatory Crosstalk Between Human Endogenous Retroviruses, HIV, and EBV, in Lymphoma
淋巴瘤中人内源性逆转录病毒、HIV 和 EBV 之间的监管串扰
  • 批准号:
    10228431
  • 财政年份:
    2021
  • 资助金额:
    $ 44.89万
  • 项目类别:
Regulatory Crosstalk Between Human Endogenous Retroviruses, HIV, and EBV, in Lymphoma
淋巴瘤中人内源性逆转录病毒、HIV 和 EBV 之间的监管串扰
  • 批准号:
    10616708
  • 财政年份:
    2021
  • 资助金额:
    $ 44.89万
  • 项目类别:
Regulatory Crosstalk Between Human Endogenous Retroviruses, HIV, and EBV, in Lymphoma
淋巴瘤中人内源性逆转录病毒、HIV 和 EBV 之间的监管串扰
  • 批准号:
    10398963
  • 财政年份:
    2021
  • 资助金额:
    $ 44.89万
  • 项目类别:
(PQ 6) New Models of KSHV Oncogenesis and KS Immune Environment
(PQ 6) KSHV 肿瘤发生和 KS 免疫环境的新模型
  • 批准号:
    10737765
  • 财政年份:
    2020
  • 资助金额:
    $ 44.89万
  • 项目类别:
(PQ 6) New Models of KSHV Oncogenesis and KS Immune Environment
(PQ 6) KSHV 肿瘤发生和 KS 免疫环境的新模型
  • 批准号:
    10397107
  • 财政年份:
    2020
  • 资助金额:
    $ 44.89万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了